Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault
Watch Eli Lilly and's latest callEli Lilly and (NYSE:LLY) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Eli Lilly and (NYSE:LLY) Q2 2026 Earnings CallEli Lilly and's next earnings callEli Lilly and (NYSE:LLY) Q3 2026 Earnings Call · Oct 29, 2026 at 10:00 AM EDTRegister
The original release is unavailable here.
Story so far
Earlier from Eli Lilly and
- Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
- Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth
- GLP-1 Receptor Agonist Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Eli Lilly and Company, Sanofi
- Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
- In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Later from Eli Lilly and
- Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
- Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight by up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Follow Eli Lilly and into a list and get an email when it puts out news.
Follow Eli Lilly and